Iovance Biotherapeutics (IOVA) Profit After Tax (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Profit After Tax for 17 consecutive years, with -$79.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 31.95% year-over-year to -$79.0 million; the TTM figure through Mar 2026 stood at -$353.8 million (up 5.74% YoY), while the FY2025 annual figure was -$391.0 million, down 5.05% from the prior year.
• Profit After Tax declined to -$79.0 million in Q1 2026 per IOVA's latest filing, from -$71.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$71.9 million in Q4 2025 and bottomed at -$116.4 million in Q4 2023.
• Historically, Profit After Tax has averaged -$98.9 million across 5 years, with a median of -$99.6 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax retreated 22.12% — and 2024, when it soared 32.5%.
• Iovance Biotherapeutics' Profit After Tax stood at -$105.3 million in 2022, then dropped by 10.5% to -$116.4 million in 2023, then jumped by 32.5% to -$78.6 million in 2024, then advanced by 8.5% to -$71.9 million in 2025, then dropped by 9.97% to -$79.0 million in 2026.
• Business Quant data shows IOVA's Profit After Tax at -$79.0 million in Q1 2026, -$71.9 million in Q4 2025, and -$91.3 million in Q3 2025.